Nontuberculous mycobacterial infections in children with inborn errors of the immune system
Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene diso...
Gespeichert in:
Veröffentlicht in: | The Journal of infection 2014-01, Vol.68, p.S134-S150 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S150 |
---|---|
container_issue | |
container_start_page | S134 |
container_title | The Journal of infection |
container_volume | 68 |
creator | Haverkamp, Margje H van de Vosse, Esther van Dissel, Jaap T |
description | Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified. |
doi_str_mv | 10.1016/j.jinf.2013.09.024 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1540221039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0163445313002910</els_id><sourcerecordid>1490730862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</originalsourceid><addsrcrecordid>eNqNkk2L1TAUhoMoznX0D7iQLt20nny0uQERZPALBmehrlyE9vSUm9omY9Iq999Pyh1duHBmERLCc1445zmMPedQceDNq7EanR8qAVxWYCoQ6gHb8VqKUmglHrJdhmSpVC3P2JOURgAw0jSP2ZlQnJu9aHbs--fgl7WjiOsU1lTMRwxdiwtF105FjidcXPApPws8uKmP5Ivfbjnkjy5EX1CMIaYiDMVyoMLN8-qpSMe00PyUPRraKdGz2_ucfXv_7uvFx_Ly6sOni7eXJSqtl7JG0Q8NqaHX2GiDRuyh6fZGm77FtgY0puadaRWQEbo3gMQ5B1Ach8ZwlOfs5Sn3OoafK6XFzi4hTVPrKfdkea1ACA7S3AOFWqp89N2oMqAl7BuRUXFCMYaUIg32Orq5jUfLwW6q7Gg3VXZTZcHYrCoXvbjNX7uZ-r8lf9xk4PUJoDy7X46iTejII_UuZiu2D-7_-W_-KcfJeYft9IOOlMawRp-tWG6TsGC_bMuy7QqXAMLkad0Av8C5tw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490730862</pqid></control><display><type>article</type><title>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Haverkamp, Margje H ; van de Vosse, Esther ; van Dissel, Jaap T</creator><creatorcontrib>Haverkamp, Margje H ; van de Vosse, Esther ; van Dissel, Jaap T</creatorcontrib><description>Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.</description><identifier>ISSN: 0163-4453</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/j.jinf.2013.09.024</identifier><identifier>PMID: 24119826</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Child ; Child, Preschool ; Children ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy - methods ; Indexing in process ; Infectious Disease ; Interferon-gamma - therapeutic use ; MSMD ; Mutation ; Mycobacterial infection ; Mycobacterium ; Mycobacterium Infections, Nontuberculous - complications ; Mycobacterium Infections, Nontuberculous - epidemiology ; Mycobacterium Infections, Nontuberculous - genetics ; Mycobacterium Infections, Nontuberculous - immunology ; Mycobacterium Infections, Nontuberculous - therapy ; Nontuberculous Mycobacteria - isolation & purification ; Salmonella ; Salmonella - isolation & purification ; Salmonella Infections - epidemiology ; Salmonella Infections - genetics ; Salmonella Infections - immunology ; Salmonella Infections - therapy</subject><ispartof>The Journal of infection, 2014-01, Vol.68, p.S134-S150</ispartof><rights>The British Infection Association</rights><rights>2013 The British Infection Association</rights><rights>Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</citedby><cites>FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jinf.2013.09.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24119826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haverkamp, Margje H</creatorcontrib><creatorcontrib>van de Vosse, Esther</creatorcontrib><creatorcontrib>van Dissel, Jaap T</creatorcontrib><title>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><description>Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.</description><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Indexing in process</subject><subject>Infectious Disease</subject><subject>Interferon-gamma - therapeutic use</subject><subject>MSMD</subject><subject>Mutation</subject><subject>Mycobacterial infection</subject><subject>Mycobacterium</subject><subject>Mycobacterium Infections, Nontuberculous - complications</subject><subject>Mycobacterium Infections, Nontuberculous - epidemiology</subject><subject>Mycobacterium Infections, Nontuberculous - genetics</subject><subject>Mycobacterium Infections, Nontuberculous - immunology</subject><subject>Mycobacterium Infections, Nontuberculous - therapy</subject><subject>Nontuberculous Mycobacteria - isolation & purification</subject><subject>Salmonella</subject><subject>Salmonella - isolation & purification</subject><subject>Salmonella Infections - epidemiology</subject><subject>Salmonella Infections - genetics</subject><subject>Salmonella Infections - immunology</subject><subject>Salmonella Infections - therapy</subject><issn>0163-4453</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk2L1TAUhoMoznX0D7iQLt20nny0uQERZPALBmehrlyE9vSUm9omY9Iq999Pyh1duHBmERLCc1445zmMPedQceDNq7EanR8qAVxWYCoQ6gHb8VqKUmglHrJdhmSpVC3P2JOURgAw0jSP2ZlQnJu9aHbs--fgl7WjiOsU1lTMRwxdiwtF105FjidcXPApPws8uKmP5Ivfbjnkjy5EX1CMIaYiDMVyoMLN8-qpSMe00PyUPRraKdGz2_ucfXv_7uvFx_Ly6sOni7eXJSqtl7JG0Q8NqaHX2GiDRuyh6fZGm77FtgY0puadaRWQEbo3gMQ5B1Ach8ZwlOfs5Sn3OoafK6XFzi4hTVPrKfdkea1ACA7S3AOFWqp89N2oMqAl7BuRUXFCMYaUIg32Orq5jUfLwW6q7Gg3VXZTZcHYrCoXvbjNX7uZ-r8lf9xk4PUJoDy7X46iTejII_UuZiu2D-7_-W_-KcfJeYft9IOOlMawRp-tWG6TsGC_bMuy7QqXAMLkad0Av8C5tw</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Haverkamp, Margje H</creator><creator>van de Vosse, Esther</creator><creator>van Dissel, Jaap T</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20140101</creationdate><title>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</title><author>Haverkamp, Margje H ; van de Vosse, Esther ; van Dissel, Jaap T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Indexing in process</topic><topic>Infectious Disease</topic><topic>Interferon-gamma - therapeutic use</topic><topic>MSMD</topic><topic>Mutation</topic><topic>Mycobacterial infection</topic><topic>Mycobacterium</topic><topic>Mycobacterium Infections, Nontuberculous - complications</topic><topic>Mycobacterium Infections, Nontuberculous - epidemiology</topic><topic>Mycobacterium Infections, Nontuberculous - genetics</topic><topic>Mycobacterium Infections, Nontuberculous - immunology</topic><topic>Mycobacterium Infections, Nontuberculous - therapy</topic><topic>Nontuberculous Mycobacteria - isolation & purification</topic><topic>Salmonella</topic><topic>Salmonella - isolation & purification</topic><topic>Salmonella Infections - epidemiology</topic><topic>Salmonella Infections - genetics</topic><topic>Salmonella Infections - immunology</topic><topic>Salmonella Infections - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haverkamp, Margje H</creatorcontrib><creatorcontrib>van de Vosse, Esther</creatorcontrib><creatorcontrib>van Dissel, Jaap T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haverkamp, Margje H</au><au>van de Vosse, Esther</au><au>van Dissel, Jaap T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>68</volume><spage>S134</spage><epage>S150</epage><pages>S134-S150</pages><issn>0163-4453</issn><eissn>1532-2742</eissn><abstract>Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24119826</pmid><doi>10.1016/j.jinf.2013.09.024</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-4453 |
ispartof | The Journal of infection, 2014-01, Vol.68, p.S134-S150 |
issn | 0163-4453 1532-2742 |
language | eng |
recordid | cdi_proquest_miscellaneous_1540221039 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Child Child, Preschool Children Hematopoietic Stem Cell Transplantation Humans Immunotherapy - methods Indexing in process Infectious Disease Interferon-gamma - therapeutic use MSMD Mutation Mycobacterial infection Mycobacterium Mycobacterium Infections, Nontuberculous - complications Mycobacterium Infections, Nontuberculous - epidemiology Mycobacterium Infections, Nontuberculous - genetics Mycobacterium Infections, Nontuberculous - immunology Mycobacterium Infections, Nontuberculous - therapy Nontuberculous Mycobacteria - isolation & purification Salmonella Salmonella - isolation & purification Salmonella Infections - epidemiology Salmonella Infections - genetics Salmonella Infections - immunology Salmonella Infections - therapy |
title | Nontuberculous mycobacterial infections in children with inborn errors of the immune system |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A05%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nontuberculous%20mycobacterial%20infections%20in%20children%20with%20inborn%20errors%20of%20the%20immune%20system&rft.jtitle=The%20Journal%20of%20infection&rft.au=Haverkamp,%20Margje%20H&rft.date=2014-01-01&rft.volume=68&rft.spage=S134&rft.epage=S150&rft.pages=S134-S150&rft.issn=0163-4453&rft.eissn=1532-2742&rft_id=info:doi/10.1016/j.jinf.2013.09.024&rft_dat=%3Cproquest_cross%3E1490730862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490730862&rft_id=info:pmid/24119826&rft_els_id=1_s2_0_S0163445313002910&rfr_iscdi=true |